indan-2,2-dicarboxylic acid ethyl ester | 83721-29-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: indan-2,2-dicarboxylic acid ethyl ester
• 英文别名: 2-(Ethoxycarbonyl)indane-2-carboxylic acid；2-ethoxycarbonyl-1,3-dihydroindene-2-carboxylic acid
• CAS: 83721-29-3
• 化学式: C₁₃H₁₄O₄
• mdl: MFCD28897467
• 分子量: 234.252
• InChiKey: BINSXNDTYVKFMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  indan-2,2-dicarboxylic acid ethyl ester 以48%的产率得到indan-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  Structure-activity studies of configurationally rigid arylprostaglandins

  摘要：

  Potent, albeit nonselective, smooth-muscle stimulant activity has been previously reported for 16-phenoxy- and 17-phenylprostaglandins, a finding that led to the design and development of the tissue-selective uterine stimulant sulprostone. As an extension of this work, analogues incorporating the 16-phenoxy and 17-phenyl substituents into the rigid indanyl, tetrahydronaphthyl, dihydrobenzofuryl, and dihydrobenzopyranyl ring systems were prepared and evaluated for uterine stimulant activity in vitro and diarrheal effects in vivo. Since these cyclic groups, with the exception of the indanyl, contain a chiral center, both optical antipodes were prepared. These studies demonstrate that ring size, heteroatom, and absolute configuration at C-16 are important determinants for potency and selectivity.

  DOI：

  10.1021/jm00357a004
• 作为产物：
  描述：

  二乙基1,3-二氢-2H-茚-2,2-二羧酸酯 在 氢氧化钾 作用下， 以 乙醇 、 水 为溶剂， 反应 48.0h， 生成 indan-2,2-dicarboxylic acid ethyl ester
  参考文献：
  名称：

  Bis-Substituted Malonic Acid Hydroxamate Derivatives as Inhibitors of Human Neutrophil Collagenase (MMP8)

  摘要：

  Malonic acid hydroxamate derivatives bis-substituted at the methylene group were synthesized as potential nonpeptidic inhibitors of human neutrophil collagenase (MMP8). The presence of an aromatic residue both at the C2 malonic acid position and in the C-terminal tail for hydrophobic interactions with the surface-exposed S1 binding site and the S1' pocket of the enzyme, respectively, was found to be sufficient for submicromolar inhibition potencies. For optimal insertion of the aryl amide group into the hydrophobic S1' pocket, spacing of the C-terminal phenyl group by at least a SC-chain was required. In view of these results the achiral indan-2,2-dicarboxylic acid was used to mimic the 2-benzyl-2-methylmalonic acid residue, and its derivatization to the 3-phenylpropyl amide hydroxamate produced a potent, achiral, low-mass inhibitor of MMP8 (K-i = 0.3 mu M), the binding mode of which was unambiguously determined by X-ray crystallographic analysis.

  DOI：

  10.1021/jm980112p

文献信息

• Hydantoin derivative as metalloprotease inhibitor
  申请人：FUJIREBIO INC.

  公开号：EP0640594A1

  公开（公告）日：1995-03-01

  A hydantoin derivative represented by formula (I): wherein the all symbols are defined in the disclosure. The hydantoin derivative has an inhibitory activity on metalloprotease and hence is useful as analgesic and cardiovascular drug.

  一种以化学式(I)表示的噻唑烷酮衍生物：其中所有符号均在披露中定义。该噻唑烷酮衍生物具有对金属蛋白酶的抑制活性，因此可用作镇痛和心血管药物。
• SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS
  申请人：CAULFIELD Thomas J.

  公开号：US20100113462A1

  公开（公告）日：2010-05-06

  The present invention relates to novel compounds of the formula I: wherein in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, Crohn's Disease, associated with the modulation of the human CXCR5 receptor.

  本发明涉及公式I的新化合物：其中在其任何立体异构形式或立体异构形式的混合物中以任何比例，或其生理上可接受的盐，其中取代基如此描述。这些创新化合物具有CXCR5抑制活性，特别适用于治疗或预防各种炎症性疾病，例如类风湿性关节炎，多发性硬化症，红斑狼疮，克罗恩病，与人类CXCR5受体调节相关。
• Substituted benzoylamino-indan-2-carboxylic acids and related compounds
  申请人：Caulfield Thomas Joseph

  公开号：US08569535B2

  公开（公告）日：2013-10-29

  The present invention relates to novel compounds of the formula Ia: in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity, and are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, Crohn's Disease, associated with the modulation of the human CXCR5 receptor.

  本发明涉及公式Ia的新化合物：以其立体异构体形式或任何比例的立体异构体混合物或其生理上可接受的盐，其中取代基如本文所述。这些创新化合物具有CXCR5抑制活性，并且在治疗或预防各种炎症性疾病方面特别有用，例如类风湿性关节炎，多发性硬化症，狼疮，克隆氏病，与人类CXCR5受体调节有关。
• WO2008/151211
  申请人：——

  公开号：——

  公开（公告）日：——
• Synthesis and evaluation of novel 1-(2-acylhydrazinocarbonyl)-cycloalkyl carboxamides as interleukin-1β converting enzyme (ICE) inhibitors
  作者：David L. Soper、Justin Sheville、Steven V. O’Neil、Yili Wang、Michael C. Laufersweiler、Kofi A. Oppong、John A. Wos、Christopher D. Ellis、Amy N. Fancher、Wei Lu、Maureen K. Suchanek、Richard L. Wang、Biswanath De、Thomas P. Demuth

  DOI：10.1016/j.bmcl.2006.05.076

  日期：2006.8

  Novel 1-(2-acylhydrazinocarbonyl)cycloalkyl carboxamides were designed as peptidomimetic inhibitors of interleukin-1 beta converting enzyme (ICE). A short synthesis was developed and moderately potent ICE inhibitors were identified (IC50 values < 100 nM). Most of the synthesized examples were selective for ICE versus the related cysteine proteases caspase-3 and caspase-8, although several dual-acting inhibitors of ICE and caspase-8 were identified. Several of the more potent ICE inhibitors were also shown to inhibit IL-1 beta production in a whole cell assay (IC50 < 500 nM). (c) 2006 Elsevier Ltd. All rights reserved.